These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1532818)

  • 41. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
    Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures.
    Richards JO; Treisman J; Garlie N; Hanson JP; Oaks MK
    Cytometry A; 2012 May; 81(5):374-81. PubMed ID: 22467596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
    Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
    Thibault C; Nelson H; Chapoval AI
    Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes.
    Mansfield PF; Salmeron MA; Rosenblum MG; Itoh K
    Int J Cancer; 1991 Sep; 49(3):356-61. PubMed ID: 1917133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
    Demotte N; Wieërs G; Van Der Smissen P; Moser M; Schmidt C; Thielemans K; Squifflet JL; Weynand B; Carrasco J; Lurquin C; Courtoy PJ; van der Bruggen P
    Cancer Res; 2010 Oct; 70(19):7476-88. PubMed ID: 20719885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-infiltrating CD3- NK cells are more effective than CD3+ T cells in killing autologous melanoma cells.
    Azogui O; Avril MF; Margulis A; Guillard M; Caillou B; Prade M
    J Invest Dermatol; 1991 Sep; 97(3):425-9. PubMed ID: 1831465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
    Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.
    Fidler IJ; Bucana C
    Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.
    Gorter A; Krüse KM; Schrier PI; Fleuren GJ; van de Griend RJ
    Clin Exp Immunol; 1992 Jan; 87(1):111-6. PubMed ID: 1531120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heteroconjugated antibodies enhance lymphocyte-mediated tumour cell lysis in vitro and in vivo.
    Reid I; Lundy J; Monson J; Nelson H; Ramsay P; Ilstrup D; Donohue J
    Br J Surg; 1992 Jul; 79(7):628-32. PubMed ID: 1386550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The effect of anti-ICAM-1/LAF-1 McAb on the cytotoxicity of tumor infiltrating lymphocytes from oral squamous cell carcinoma].
    Yang H; Luo J; Li J
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Apr; 21(2):107-8, 111. PubMed ID: 12838691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma.
    Maeda K; Lafreniere R; Jerry LM
    J Invest Dermatol; 1991 Aug; 97(2):183-9. PubMed ID: 2071934
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibody.
    Schoof DD; Jung SE; Eberlein TJ
    Int J Cancer; 1989 Aug; 44(2):219-24. PubMed ID: 2503456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The bispecific antibody 500A2 x 96.5 targets T-lymphocytes activated in vivo with staphylococcal enterotoxin B (SEB) against CL62 melanoma cells in vitro.
    Reid IM; Lundy JK; Donohue JH
    Surg Oncol; 1994 Oct; 3(5):279-85. PubMed ID: 7889221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice.
    Riedle S; Rösel M; Zöller M
    Int J Cancer; 1998 Mar; 75(6):908-18. PubMed ID: 9506537
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.
    Nijhuis EW; vd Wiel-van Kemenade E; Figdor CG; van Lier RA
    Cancer Immunol Immunother; 1990; 32(4):245-50. PubMed ID: 2175673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.